Clinical trials in neuroprotection: 23 - 25 January 2003, Key Biscayne, Florida, USA

Expert Opinion on Emerging Drugs

Volumn 8, Issue 1, 2003, Pages 267-271

  Dichter, Marc A ^a   Locke, Rachel E ^a  

^a Penn Spine Center   (United States)

Author keywords

ALS; Alzheimer's disease; Animal models; Brain; Clinical trials; Epilepsy; Neonatal surgery; Neurodegeneration; Neurological disorder; Neuroprotection; Neuroscience; Parkinson's disease; Spinal cord injury; Stroke; Traumatic brain injury

Indexed keywords

ANTIOXIDANT; BIOLOGICAL MARKER; CALCIUM CHANNEL BLOCKING AGENT; CASPASE INHIBITOR; NEUROPROTECTIVE AGENT; NIMODIPINE; PROTEIN BAX; PROTEIN BCL 2; TISSUE PLASMINOGEN ACTIVATOR;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; ASSAY; BRAIN TOMOGRAPHY; CELL LOSS; CLINICAL TRIAL; CONFERENCE PAPER; DEGENERATIVE DISEASE; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; EPILEPSY; GENE TARGETING; HEAD INJURY; HUMAN; INFLAMMATION; NERVE CELL; NERVE CELL LESION; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROPROTECTION; NEUROTRANSMISSION; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; SPINAL CORD INJURY; STROKE;

ANIMALS; CLINICAL TRIALS; HUMANS; NEUROPROTECTIVE AGENTS;

EID: 0037642513     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.8.1.267     Document Type: Conference Paper

References (0)